vs
Revvity（RVTY）とWest Pharmaceutical Services（WST）の財務データ比較。上の社名をクリックして会社を切り替えられます
West Pharmaceutical Servicesの直近四半期売上が大きい（$805.0M vs $772.1M、Revvityの約1.0倍）。West Pharmaceutical Servicesの純利益率が高く（16.4% vs 12.7%、差は3.7%）。West Pharmaceutical Servicesの前年同期比売上増加率が高い（7.5% vs 5.9%）。West Pharmaceutical Servicesの直近四半期フリーキャッシュフローが多い（$175.0M vs $161.8M）。過去8四半期でRevvityの売上複合成長率が高い（9.0% vs 7.6%）
レブィティ（Revvity, Inc.）は米国のライフサイエンス・診断事業を手がける企業で、製薬およびバイオテクノロジー業界を主な顧客とし、特に新たな細胞治療や遺伝子治療の開発に関連するサービス・製品を提供している。前身は多岐にわたる事業を展開してきた老舗企業パーキンエルマーである。
ウェストファーマシューティカルサービスは注射用医薬品の包装および投与システムを設計・製造する企業で、1923年に設立され、本社はペンシルベニア州エクストンにあります。創業当初は注射薬包装用ゴム部品を生産し、ペニシリンやインスリンの製造元に無菌対応の製品を提供していました。
RVTY vs WST — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $772.1M | $805.0M |
| 純利益 | $98.4M | $132.1M |
| 粗利率 | — | 37.8% |
| 営業利益率 | 14.5% | 19.5% |
| 純利益率 | 12.7% | 16.4% |
| 売上前年比 | 5.9% | 7.5% |
| 純利益前年比 | 3.9% | 1.5% |
| EPS（希薄化後） | $0.86 | $1.82 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $772.1M | $805.0M | ||
| Q3 25 | $698.9M | $804.6M | ||
| Q2 25 | $720.3M | $766.5M | ||
| Q1 25 | $664.8M | $698.0M | ||
| Q4 24 | $729.4M | $748.8M | ||
| Q3 24 | $684.0M | $746.9M | ||
| Q2 24 | $691.7M | $702.1M | ||
| Q1 24 | $649.9M | $695.4M |
| Q4 25 | $98.4M | $132.1M | ||
| Q3 25 | $46.7M | $140.0M | ||
| Q2 25 | $53.9M | $131.8M | ||
| Q1 25 | $42.2M | $89.8M | ||
| Q4 24 | $94.6M | $130.1M | ||
| Q3 24 | $94.4M | $136.0M | ||
| Q2 24 | $55.4M | $111.3M | ||
| Q1 24 | $26.0M | $115.3M |
| Q4 25 | — | 37.8% | ||
| Q3 25 | 53.6% | 36.6% | ||
| Q2 25 | 54.5% | 35.7% | ||
| Q1 25 | 56.5% | 33.2% | ||
| Q4 24 | — | 36.5% | ||
| Q3 24 | 56.3% | 35.4% | ||
| Q2 24 | 55.7% | 32.8% | ||
| Q1 24 | 54.6% | 33.1% |
| Q4 25 | 14.5% | 19.5% | ||
| Q3 25 | 11.7% | 20.8% | ||
| Q2 25 | 12.6% | 20.1% | ||
| Q1 25 | 10.9% | 15.3% | ||
| Q4 24 | 16.3% | 21.3% | ||
| Q3 24 | 14.3% | 21.6% | ||
| Q2 24 | 12.4% | 18.0% | ||
| Q1 24 | 6.8% | 17.7% |
| Q4 25 | 12.7% | 16.4% | ||
| Q3 25 | 6.7% | 17.4% | ||
| Q2 25 | 7.5% | 17.2% | ||
| Q1 25 | 6.4% | 12.9% | ||
| Q4 24 | 13.0% | 17.4% | ||
| Q3 24 | 13.8% | 18.2% | ||
| Q2 24 | 8.0% | 15.9% | ||
| Q1 24 | 4.0% | 16.6% |
| Q4 25 | $0.86 | $1.82 | ||
| Q3 25 | $0.40 | $1.92 | ||
| Q2 25 | $0.46 | $1.82 | ||
| Q1 25 | $0.35 | $1.23 | ||
| Q4 24 | $0.77 | $1.78 | ||
| Q3 24 | $0.77 | $1.85 | ||
| Q2 24 | $0.45 | $1.51 | ||
| Q1 24 | $0.21 | $1.55 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $919.9M | $791.3M |
| 総負債低いほど良い | — | $202.8M |
| 株主資本純資産 | $7.3B | $3.2B |
| 総資産 | $12.2B | $4.3B |
| 負債/資本比率低いほどレバレッジが低い | — | 0.06× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $919.9M | $791.3M | ||
| Q3 25 | $931.4M | $628.5M | ||
| Q2 25 | $991.8M | $509.7M | ||
| Q1 25 | $1.1B | $404.2M | ||
| Q4 24 | $1.2B | $484.6M | ||
| Q3 24 | $1.2B | $490.9M | ||
| Q2 24 | $2.0B | $446.2M | ||
| Q1 24 | $1.7B | $601.8M |
| Q4 25 | — | $202.8M | ||
| Q3 25 | — | $202.7M | ||
| Q2 25 | — | $202.6M | ||
| Q1 25 | — | $202.6M | ||
| Q4 24 | — | $202.6M | ||
| Q3 24 | — | $202.6M | ||
| Q2 24 | — | $205.8M | ||
| Q1 24 | — | $206.2M |
| Q4 25 | $7.3B | $3.2B | ||
| Q3 25 | $7.4B | $3.1B | ||
| Q2 25 | $7.6B | $2.9B | ||
| Q1 25 | $7.6B | $2.7B | ||
| Q4 24 | $7.7B | $2.7B | ||
| Q3 24 | $7.9B | $2.8B | ||
| Q2 24 | $7.9B | $2.6B | ||
| Q1 24 | $7.8B | $2.7B |
| Q4 25 | $12.2B | $4.3B | ||
| Q3 25 | $12.1B | $4.1B | ||
| Q2 25 | $12.4B | $4.0B | ||
| Q1 25 | $12.4B | $3.6B | ||
| Q4 24 | $12.4B | $3.6B | ||
| Q3 24 | $12.8B | $3.7B | ||
| Q2 24 | $13.4B | $3.5B | ||
| Q1 24 | $13.4B | $3.6B |
| Q4 25 | — | 0.06× | ||
| Q3 25 | — | 0.07× | ||
| Q2 25 | — | 0.07× | ||
| Q1 25 | — | 0.08× | ||
| Q4 24 | — | 0.08× | ||
| Q3 24 | — | 0.07× | ||
| Q2 24 | — | 0.08× | ||
| Q1 24 | — | 0.08× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $182.0M | $251.1M |
| フリーキャッシュフロー営業CF - 設備投資 | $161.8M | $175.0M |
| FCFマージンFCF / 売上 | 21.0% | 21.7% |
| 設備投資強度設備投資 / 売上 | 2.6% | 9.5% |
| キャッシュ転換率営業CF / 純利益 | 1.85× | 1.90× |
| 直近12ヶ月FCF直近4四半期 | $509.4M | $468.9M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $182.0M | $251.1M | ||
| Q3 25 | $138.5M | $197.2M | ||
| Q2 25 | $134.3M | $177.1M | ||
| Q1 25 | $128.2M | $129.4M | ||
| Q4 24 | $174.2M | $190.1M | ||
| Q3 24 | $147.9M | $180.1M | ||
| Q2 24 | $158.6M | $165.0M | ||
| Q1 24 | $147.6M | $118.2M |
| Q4 25 | $161.8M | $175.0M | ||
| Q3 25 | $120.0M | $133.9M | ||
| Q2 25 | $115.5M | $101.9M | ||
| Q1 25 | $112.2M | $58.1M | ||
| Q4 24 | $149.8M | $85.2M | ||
| Q3 24 | $125.6M | $98.8M | ||
| Q2 24 | $136.6M | $64.8M | ||
| Q1 24 | $129.7M | $27.6M |
| Q4 25 | 21.0% | 21.7% | ||
| Q3 25 | 17.2% | 16.6% | ||
| Q2 25 | 16.0% | 13.3% | ||
| Q1 25 | 16.9% | 8.3% | ||
| Q4 24 | 20.5% | 11.4% | ||
| Q3 24 | 18.4% | 13.2% | ||
| Q2 24 | 19.7% | 9.2% | ||
| Q1 24 | 20.0% | 4.0% |
| Q4 25 | 2.6% | 9.5% | ||
| Q3 25 | 2.6% | 7.9% | ||
| Q2 25 | 2.6% | 9.8% | ||
| Q1 25 | 2.4% | 10.2% | ||
| Q4 24 | 3.4% | 14.0% | ||
| Q3 24 | 3.3% | 10.9% | ||
| Q2 24 | 3.2% | 14.3% | ||
| Q1 24 | 2.7% | 13.0% |
| Q4 25 | 1.85× | 1.90× | ||
| Q3 25 | 2.97× | 1.41× | ||
| Q2 25 | 2.49× | 1.34× | ||
| Q1 25 | 3.03× | 1.44× | ||
| Q4 24 | 1.84× | 1.46× | ||
| Q3 24 | 1.57× | 1.32× | ||
| Q2 24 | 2.87× | 1.48× | ||
| Q1 24 | 5.67× | 1.03× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
WST
| Proprietary Products | $661.8M | 82% |
| Contract Manufactured Products | $143.2M | 18% |
| Affiliated Entity | $3.3M | 0% |
